Thursday, September 07, 2017 8:51:14 AM
VKTZ - 1.05 Pre-market now at 1.10/1.16
BZ: Viking Therapeutics Will Provide Data From In Vivo Proof-Of-Concept Study Of VK2809 In Glycogen Storage Disease Ia: 'VK2809 Leads to Statistically Significant Reductions in Liver Triglyceride Levels and Liver Weight Compared to Controls'
BZ: Viking Therapeutics Will Provide Data From In Vivo Proof-Of-Concept Study Of VK2809 In Glycogen Storage Disease Ia: 'VK2809 Leads to Statistically Significant Reductions in Liver Triglyceride Levels and Liver Weight Compared to Controls'
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
